Non-Effervescent Gastro-Retentive Tablets For Controlled Release Of Pregabalin

The development and assessment of non-effervescent tablets are essential for ensuring the controlled release of active ingredients such as Pregabalin. Non-effervescent tablets are specifically designed to release medication gradually and consistently over an extended period, which is particularly advantageous for drugs like Pregabalin utilizing HPMC K100M and Carbopol 971P as release-retarding polymers. The objective of this study was to create and assess controlled release matrix tablets containing Pregabalin. The main purpose of this study was to develop gastroretentive tablets with floating and swelling properties for once-daily administration of pregabalin. The non-effervescent floating and swelling tablets were prepared using wet granulation and compaction, which are widely used and easily accessible. The amount of hydroxypropyl methylcellulose and crospovidone were found to be critical factors affecting in vitro dissolution and floating properties of the prepared tablets. The rationale emphasizes the limitations of immediate-release Pregabalin formulations, such as the need for multiple daily doses and potential fluctuations in drug levels, which might lead to inadequate pain control and reduced patient adherence. It underscores the necessity for a formulation that offers sustained pain relief with less frequent dosing. Enhancing Patient Compliance.: By reducing dosing frequency through controlled release, the research aims to enhance patient compliance and convenience.